Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asfotase Alfa in Adult Pediatric-Onset Hypophosphatasia (REBUILD)
NCT04189315Phase 4Withdrawn
- Sponsor
- Alexion Pharmaceuticals
- Start
- Apr 2020
- Primary completion
- Aug 2022
- Modality
- Replacement Enzymes
01
Overview
Phase 4, randomised, open-label trial of asfotase alfa in hypophosphatasia (HPP) (2 arms), sponsored by Alexion Pharmaceuticals. Primary endpoint: Change From Baseline To Week 36 In Plasma Concentrations Of Inorganic Pyrophosphate (PPi) In Group 1. Planned start Apr 2020; status: withdrawn.
02
Drugs
asfotase alfa
03
Conditions
hypophosphatasia (HPP)
Beyond the preview
Go deeper on NCT04189315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04189315.